This content is machine translated Breast Cancer Metastatic pathways in focus Surgical or radiotherapeutic treatment of regional lymph nodes prolongs breast cancer survival and reduces the likelihood of distant metastasis. However, the effect on regional lymph node recurrence appears to be…
View Post 3 min This content is machine translated Ovarian cancer and the immune system The choice of chemotherapy is crucial Chemotherapy-induced changes in the immune system can be used therapeutically in the era of immuno-oncology. Accurate characterization of immunologic effects of different agents, in addition to better risk management, will…
View Post 10 min This content is machine translated Multiple Myeloma A portrait of a multifaceted disease The introduction of new drugs has steadily improved the prognosis of patients with multiple myeloma over the past years. Diagnostics have also been expanded, in particular by cytogenetic analyses, which…
View Post 12 min This content is machine translated Interview: Prof. Dr. med. Dr. sc. nat. Heinz Läubli Promoting collaboration – at all levels Recently, Prof. Dr. Dr. Heinz Läubli, Head Physician for Oncology at the University Hospital Basel, received this year’s Annemarie Karrasch Research Award of the Basel Research Foundation propatient. Läubli’s research…
View Post 11 min This content is machine translated Aggressive lymphomas Therapy in everyday clinical practice based on current developments Lymphoma accounts for 3.8% of all new cancer diagnoses. According to the current WHO classification, there are over 75 different lymphomentities, which are treated differently. In the treatment of diffuse… CME-Test
View Post 5 min This content is machine translated News from the lung cancer pipeline First targeted substance in KRAS mutation and bispecific immunotherapy While targeted therapies in non-small cell lung cancer (NSCLC) have been on the rise for years, such an option for KRAS-mutatedtumors has been lacking. The small molecule inhibitor Sotorasib, which…
View Post 3 min This content is machine translated Sponsored Content: HRD-positive advanced ovarian cancer. New option in first-line maintenance therapy Ovarian cancer is still the most lethal gynecologic tumor and, especially in advanced stages, the risk of progression remains high even with optimal therapy [1, 2]. Thus, effective treatments that…
View Post 7 min This content is machine translated Ten years of living with Fukushima The nuclear disaster and cancer For 40 years, IPPNW, the group of International Physicians for the Prevention of Nuclear War, has been working for a world without nuclear threats. Ten years after the nuclear disaster…
View Post 3 min This content is machine translated Advanced malignant melanoma Adjuvant immunotherapy with nivolumab: promising long-term results According to current study data, more than half of the patients who received adjuvant treatment with the anti-PD-1 antibody were relapse-free after four years. This is further confirmation of the…
View Post 10 min This content is machine translated Side effect management Immune checkpoint inhibitor associated neurological side effects. Immune checkpoint inhibitors are finding increasingly widespread use in oncology with some breakthrough success. However, the activation of the immune system also triggers a wide range of side effects. Neurological… CME-Test
View Post 7 min This content is machine translated Urothelial carcinoma The role of checkpoint inhibitors Immunotherapy is also becoming increasingly important in the treatment of urothelial carcinoma. Checkpoint inhibitors are already being used successfully, particularly in advanced tumors. Now, potential applications of avelumab, atezolizumab and…
